- Home
- TRIN vs MYGN Comparison
TRIN vs MYGN Comparison
Compare TRIN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- MYGN
- Stock Information
- Founded
- TRIN 2007
- MYGN 1991
- Country
- TRIN United States
- MYGN United States
- Employees
- TRIN N/A
- MYGN N/A
- Industry
- TRIN Finance/Investors Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRIN Finance
- MYGN Health Care
- Exchange
- TRIN Nasdaq
- MYGN Nasdaq
- Market Cap
- TRIN 912.3M
- MYGN 744.7M
- IPO Year
- TRIN 2021
- MYGN 1995
- Fundamental
- Price
- TRIN $14.16
- MYGN $5.66
- Analyst Decision
- TRIN Hold
- MYGN Hold
- Analyst Count
- TRIN 3
- MYGN 15
- Target Price
- TRIN $14.83
- MYGN $15.14
- AVG Volume (30 Days)
- TRIN 837.6K
- MYGN 1.4M
- Earning Date
- TRIN 08-06-2025
- MYGN 08-05-2025
- Dividend Yield
- TRIN 14.38%
- MYGN N/A
- EPS Growth
- TRIN 37.77
- MYGN N/A
- EPS
- TRIN 2.19
- MYGN N/A
- Revenue
- TRIN $240,010,000.00
- MYGN $831,300,000.00
- Revenue This Year
- TRIN $24.11
- MYGN N/A
- Revenue Next Year
- TRIN $4.87
- MYGN $6.68
- P/E Ratio
- TRIN $6.47
- MYGN N/A
- Revenue Growth
- TRIN 30.65
- MYGN 7.38
- 52 Week Low
- TRIN $12.50
- MYGN $3.81
- 52 Week High
- TRIN $16.82
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- TRIN 44.05
- MYGN 58.80
- Support Level
- TRIN $14.11
- MYGN $4.90
- Resistance Level
- TRIN $14.32
- MYGN $5.74
- Average True Range (ATR)
- TRIN 0.22
- MYGN 0.27
- MACD
- TRIN -0.01
- MYGN 0.07
- Stochastic Oscillator
- TRIN 48.72
- MYGN 90.82
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.